[go: up one dir, main page]

US6214839B1 - Substituted 6-alkylphenanthridines - Google Patents

Substituted 6-alkylphenanthridines Download PDF

Info

Publication number
US6214839B1
US6214839B1 US09/462,507 US46250700A US6214839B1 US 6214839 B1 US6214839 B1 US 6214839B1 US 46250700 A US46250700 A US 46250700A US 6214839 B1 US6214839 B1 US 6214839B1
Authority
US
United States
Prior art keywords
hydrogen
alkoxy
alkyl
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/462,507
Other languages
English (en)
Inventor
Beate Gutterer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Assigned to BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH reassignment BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUTTERER, BEATE
Application granted granted Critical
Publication of US6214839B1 publication Critical patent/US6214839B1/en
Assigned to ALTANA PHARMA AG reassignment ALTANA PHARMA AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines

Definitions

  • the invention relates to novel 6-alkylphenanthridines which are used in the pharmaceutical industry for the production of medicaments.
  • German Patent Application DE 11 99 773 describes the preparation of 6-methyl-8,9-methylenedioxy-1,2,3,4,4a,5,6,10b-octahydrophenanthridine, which should have analgesic, antiinflammatory and anti-pyretic properties.
  • Indian Journal of Chemistry 7, 1969, 674-677 the preparation of ethyl 1,2,3,4,4a,10a-hexahydrophenanthridine-6-butyrate is described.
  • the invention thus relates to compounds of the formula I
  • R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,
  • R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,
  • R1 and R2 together are a 1-2C-alkylenedioxy group
  • R3 is hydrogen or 1-4C-alkyl
  • R31 is hydrogen or 1-4C-alkyl
  • R3 and R31 together are a 1-4C-alkylene group
  • R4 is hydrogen or 1-4C-alkyl
  • R5 is hydrogen
  • R51 is hydrogen
  • A is 1-6C-alkylene or 5-7C-cycloalkylene
  • R6 is COOR61 or CON(R62)R63, where
  • R61 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl and
  • R62 and R63 independently of one another are hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,
  • 1-4C-Alkyl represents a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl and, preferably, the ethyl and methyl radicals.
  • 1-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and, preferably, the ethoxy and methoxy radicals.
  • 3-7C-Cycloalkoxy represents cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy, of which cyclopropyloxy, cyclobutyloxy and cyclopentyloxy are preferred.
  • 3-7C-Cycloalkylmethoxy represents cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy and cycloheptylmethoxy, of which cyclopropylmethoxy, cyclobutylmethoxy and cyclopentylmethoxy are preferred.
  • 1-2C-Alkylenedioxy represents, for example, the methylenedioxy (—O—CH 2 —O—) and the ethylenedioxy radicals (—O—CH 2 —CH 2 —O—).
  • R3 and R31 together have the meaning 1-4C-alkylene
  • the positions 1 to 4 in compounds of the formula I are linked to one another by a 1-4C-alkylene bridge, 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms.
  • 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms. Examples which may be mentioned are the radicals methylene (—CH 2 —), ethylene (—CH 2 —CH 2 —), trimethylene (—CH 2 —CH 2 —CH 2 —), 1,2-dimethylethylene [—CH(CH 3 )—CH(CH 3 )—] and isopropylidene [—C(CH 3 ) 2 —].
  • 1-6C-Alkylene represents straight-chain or branched 1-6C-alkylene radicals, for example the methylene (—CH 2 —), ethylene (—CH 2 —CH 2 —), trimethylene (—CH 2 —CH 2 —CH 2 —), tetramethylene (—CH 2 —CH 2 —CH 2 —CH 2 —), 1,2-dimethyl-ethylene [—CH(CH 3 )—CH(CH 3 )—], 1,1-dimethylethylene [—C(CH 3 ) 2 —CH 2 —], 2,2-dimethylethylene [—CH 2 —C(CH 3 ) 2 —], isopropylidene [—C(CH 3 ) 2 —], 1-methylethylene [—CH(CH 3 )—CH 2 —], pentamethylene (—CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —) and the hexamethylene radicals (—CH 2 —CH 2 —CH 2 —CH 2 —CH
  • 5-7C-Cycloalkylene represents cycloalkylene radicals having 5 to 7 carbon atoms. Cyclohexylene radicals are preferred, where, for example, the 1,3- and the 1,4-cyclohexylene radicals may be mentioned.
  • 1-7C-Alkyl represents straight-chain or branched alkyl radicals having 1 to 7 carbon atoms. Examples which may be mentioned are the heptyl, isoheptyl (5-methylhexyl), hexyl, isohexyl (4-methylpentyl), neohexyl (3,3-dimethylbutyl), pentyl, isopentyl (3-methylbutyl), neopentyl (2,2-dimethylpropyl), butyl, isobutyl, sec-butyl, tert butyl, propyl, isopropyl, ethyl and methyl radicals.
  • 3-7C-Cycloalkyl represents the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl radicals.
  • 3-7C-Cycloalkylmethyl represents a methyl radical which is substituded by one of the abovementioned 3-7C-cycloalkyl radicals. Examples which may be mentioned are the cyclopentylmethyl and the cyclohexylmethyl radicals.
  • salts with bases are also suitable.
  • examples of salts with bases which may be mentioned are alkali metal (lithium, sodium, potassium) or calcium, aluminum, magnesium, titanium, ammonium, meglumine or guanidinium salts, where here too the bases are employed in salt preparation in an equimolar quantitative ratio or one differing therefrom.
  • Pharmacologically intolerable salts which may be obtained initially as process products, for example in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
  • the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula I as well as all solvents and in particular all hydrates of the salts of the compounds of formula I.
  • R1 is 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy.
  • R2 is 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy.
  • R3 is hydrogen
  • R31 is hydrogen
  • R3 and R31 together are a 1-2C-alkylene group
  • R4 is hydrogen or 1-4C-alkyl
  • R5 is hydrogen
  • R51 is hydrogen
  • R5 is R51 together are an additional bond
  • A is 1-6C-alkylene or 5-7C-cycloalkylene
  • R6 is COOR61 or CON(R62)R63, where
  • R61 is hydrogen, 1-7C-alkyl or 3-7C-cycloalkylmethyl and
  • R62 and R63 independently of one another are hydrogen or 1-7C-alkyl
  • R1 is 1-4C-alkoxy, 3-7C-cycloalkoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
  • R2 is 1-4C-alkoxy, 3-7C-cycloalkoxy or completely or predominatly fluorine-substituted 1-2C-alkoxy,
  • R3 is hydrogen
  • R31 is hydrogen
  • R3 and R31 together are a 1-2C-alkylene group
  • R4 is hydrogen or 1-4C-alkyl
  • R5 is hydrogen
  • R51 is hydrogen
  • A is 1-6C-alkylene or 5-7C-cycloalkylene
  • R6 is COOR61 or CON(R62)R63, where
  • R61 is hydrogen, 1-4C-alkyl
  • R62 and R63 independently of one another are hydrogen or 1-4C-alkyl
  • Preferred compounds of the formula I are those in which
  • R1 is 1-2C-alkoxy
  • R2 is 1-2C-alkoxy
  • R3 is hydrogen
  • R31 is hydrogen
  • R4 is hydrogen
  • R5 is hydrogen
  • R51 is hydrogen
  • A is cyclohexylene
  • R6 is COOR61, where
  • R61 is 1-4C-alkyl
  • the compounds of the formula I are chiral compounds having chiral centers in the positions 4 a and 10 b and, depending on the meaning of the substituents R3, R31, R4, R5 and R51, further chiral centers in the positions 1, 2, 3 and 4. If A represents 5-7C-cycloalkylene, depending on the regiochemistry of the substitution, 2 further chiral centers also occur within the alkylene ring. Also, if A is 1-6C-alkylene and the 1-6C-alkylene radical is branched, additional chiral centers can occur within the alkylene radical.
  • the invention therefore includes all conceivable pure diastereomers and pure enantiomers and their mixtures in any mixing ratio, including the racemates.
  • the compounds of the formula I are preferred in which the hydrogen atoms in the positions 4 a and 10 b are cis to one another. Particularly preferred here are the pure cis diastereomers and the pure cis enantiomers and their mixtures in any mixing ratio and including the racemates.
  • the enantiomers can be separated in a manner known per se (for example by preparation and separation of appropriate diastereoisomeric compounds). Preferably, a separation of enantiomers takes place at the stage of the starting compounds of the formula III
  • enantiomerically pure starting compounds of the formula III can also be prepared via asymmetric syntheses.
  • the stereochemistry within the alkylene radical is determined by the stereochemistry of the starting alkylene compounds used for the synthesis.
  • the invention further relates to a process for the preparation of the compounds of the formula I, in which R1, R2, R3, R31, R4, R5, R51, A and R6 have the meanings indicated above, and their salts.
  • the process comprises cyclocondensing compounds of the formula II
  • R1, R2, R3, R31, R4, R5, R51, A and R6 have the meanings indicated above, and, if desired, then converting the compounds of the formula I obtained into their salts, or, if desired, then converting salts of the compounds of the formula I obtained into the free compounds.
  • compounds of the formula I obtained can be converted into further compounds of the formula I by derivatization.
  • the corresponding acids can be obtained from compounds of the formula I, in which R6 is an ester group, by acidic or alkaline hydrolysis
  • the corresponding amides can be prepared by reaction with amines of the formula HN(R62)R63 or alternatively corresponding esters can be prepared by transesterification of esters of the formula I or by esterification of acids of the formula I.
  • the reactions are expediently carried out analogously to the methods known to the person skilled in the art.
  • Cyclocondensation is carried out in a manner known per se to the person skilled in the art according to Bischler-Napieralski (e.g. as described in J. Chem. Soc., 1956, 4280-4282) in the presence of a suitable condensing agent, such as, for example, polyphosphoric acid, phosphorus pentachloride phosphorus trichloride, phosphorus pentoxide, thionyl chloride or preferably phosphorous oxychloride, in a suitable inert solvent, e.g.
  • a chlorinated hydrocarbon such as chloroform
  • a cyclic hydrocarbon such as toluene or xylene
  • another inert solvent such as acetonitrile
  • an excess of condensing agent preferably at elevated temperature, in particular at the boiling temperature of the solvent or condensing agent used.
  • the compounds of the formula III can be prepared, for example, from compounds of the formula IV
  • Reduction is carried out in a manner known to the person skilled in the art, for example as described in J. Org. Chem. 1962, 27, 4426 or as described in the following examples.
  • reduction is carried out by catalytic hydrogenation, e.g. in the presence of Raney nickel, in a lower alcohol such as methanol or ethanol at room temperature and under normal or elevated pressure.
  • a catalytic amount of an acid such as, for example, hydrochloric acid, can be added to the solvent.
  • the compounds of the formula III in which R1, R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 together are an additional bond, can be prepared from the corresponding compounds of the formula IV by selective reduction of the nitro group in a manner known to the person skilled in the art, for example in the presence of Raney nickel in a lower alcohol as a solvent using hydrazine hydrate as a hydrogen donor.
  • the compounds of the formula IV in which R1, R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 are hydrogen, are either known or can be prepared from corresponding compounds of the formula IV, in which R5 and R51 together are an additional bond.
  • the reaction can be carried out in a manner known to the person skilled in the art, preferably by hydrogenation in the presence of a catalyst, such as, for example, palladium on activated carbon, e.g. as described in J. Chem. Soc. (C), 1971, 1805-1808.
  • R3, R31 and R4 have the abovementioned meanings.
  • Cycloaddition is carried out here in a manner known to the person skilled in the art according to Diels-Alder, e.g. as described in J. Amer. Chem. Soc. 1957, 79, 6559 or in J. Org. Chem. 1952, 17, 581 or as described in the following examples.
  • the compounds of the formulas V and VI are either known or can be prepared in a known manner.
  • the compounds of the formula V can be prepared, for example, from corresponding compounds of the formula VII in a manner known to the person skilled in the art, as described, for example, in J. Chem. Soc. 1951, 2524 or in J. Org. Chem. 1944, 9, 170 or as described in the following examples.
  • R1 and R2 have the meanings indicated above, are either known or can be prepared in a manner known to the person skilled in the art, as described, for example, in Ber. Dtsch. Chem. Ges. 1925, 58, 203.
  • the isolation and purification of the substances according to the invention is carried out in a manner known per se, for example by distilling off the solvent in vacuo and recrystallizing the resulting residue from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example column chromatography on suitable support material.
  • Salts are obtained by dissolving the free compound in a suitable solvent, e.g. in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol), which contains the desired acid or base, or to which the desired acid or base is then added.
  • a suitable solvent e.g. in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol), which contains the desired acid or base, or to which the desired acid or base is then added.
  • the salts are obtained by filtering, reprecipitation, precipitation with a nonsolvent for the addition salt or by evaporation of the solvent.
  • Salts obtained can be converted by alkalization or by acidification into the free compounds, which in turn can be converted into salts. In this manner, pharmacologically intolerable salts can be converted into pharmacologically to
  • m.p. stands for melting point, h for hour(s), RT for room temperature, EF for empirical formula, MW for molecular weight, calc. for calculated, fnd for found.
  • Elemental analysis calc.: C, 72.15; H, 8.33; N, 3.51.
  • fnd C, 72.07; H, 8.22; N, 3.42.
  • the compounds according to the invention have useful pharmacological properties which make them industrially utilizable.
  • PDE selective cyclic nucleotide phosphodiesterase
  • bronchial therapeutics for the treatment of airway obstructions on account of their dilating action but also on account of their respiratory rate- or respiratory drive-increasing action
  • erectile disfunction on account of their vascular dilating action, but on the other hand especially for the treatment of disorders, in particular of an inflammatory nature, e.g.
  • the compounds according to the invention are distinguished by a low toxicity, a good enteral absorption (high bioavailability), a large therapeutic breadth and the absence of significant side effects.
  • the compounds according to the invention can be employed in human and veterinary medicine as therapeutics, where they can be used, for example, for the treatment and prophylaxis of the following illnesses;: acute and chronic (in particular inflammatory and allergen-induced) airway disorders of varying origin (bronchitis, allergic bronchitis, bronchial asthma); dermatoses (especially of proliferative, inflammatory and allergic type) such as psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, Lichen simplex, sunburn, pruritus in the anogenital area, alopecia areata, hypertropic scars, discoid lupus erythematosus, follicular and widespread pyodermias, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders; disorders which
  • the invention further relates to a method for the treatment of mammals, including humans, which are suffering from one of the abovementioned illnesses.
  • the method is characterized in that a therapeutically active and pharmacologically effective and tolerable amount of one or more of the compounds according to the invention is administered to the ill mammal.
  • the invention further relates to the compounds according to the invention for use in the treatment and/or prophylaxis of illnesses, especially the illnesses mentioned.
  • the invention also relates to the use of the compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the illnesses mentioned.
  • the invention furthermore relates to medicaments for the treatment and/or prophylaxis of the illnesses mentioned, which contain one or more of the compounds according to the invention.
  • the medicaments are prepared by processes which are known per se and familiar to the person skilled in the art.
  • auxiliaries which are suitable for the desired pharmaceutical formulations on account of this expert knowledge.
  • solvents for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers or permeation promoters, can be used.
  • the compounds according to the invention are preferably also administered by inhalation.
  • these are either administered directly as a powder (preferably in micronized form) or by atomizing solutions or suspensions which contain them.
  • 4 reference is made, for example, to the details in European Patent 163 965.
  • the compounds according to the invention are in particular administered in the form of those medications which are suitable for topical application.
  • suitable pharmaceutical formulations are, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions.
  • the medicaments according to the invention are prepared by processes known per se.
  • the dosage of the active compounds is carried out in the order of magnitude customary for PDE inhibitors.
  • Topical applications forms (such as ointments) for the treatment of dermatoses thus contain the active compounds in a concentration of, for example, 0.1-99%.
  • the dose for administration by inhalation is customarily between 0.1 and 3 mg per day.
  • the customary dose in the case of systemic therapy (p.o. or i.v.) is between 0.03 and 3 mg/kg per day.
  • FMLP N-formyl-methionyl-leucyl-phenylatanine
  • chemiluminescence Mc Phail L C, Strum S L, Leone P A and Sozzani S. The neutrophil respiratory burst mechanism.
  • Coffey R G Marcel Decker, Inc., New York-Basel-Hong Kong
  • Substances which inhibit chemiluminescene and cytokine secretion and the secretion of proinflammatory mediators on inflammatory cells are those which inhibit PDE 4.
  • This isoenzyme of the phosphodiesterase families is particularly represented in granulocytes. Its inhibition leads to an increase in the intracellular cyclic AMP concentration and thus to the inhibition of cellular activation. PDE 4 inhibition by the substances according to the invention is thus a central indicator for the suppression of inflammatory processes.
  • the activity test was carried out by the method of Bauer and Schwabe, which was adapted to microtiter plates (Naunyn-Schmiedeberg's Arch, Pharmacol. 1980, 311, 193-198).
  • the PDE reaction is carried out in the first step.
  • the resultant 5′-nucleotide is cleaved to give the uncharged nucleoside by a 5′-nucleotidase of the snake venom from Crotalus atrox.
  • the nucleoside is separated from the remaining charged substrate on ion exchange columns. The columns are eluted with 2 ml of 30 mM ammonium formate (pH 6.0) directly into minivials to which 2 ml of scintillation fluid is additionally added for counting.
  • inhibitory values determined for the compounds according to the invention [inhibitory concentration as —Iog IC 50 (mol/l)] follow from Table A below, in which the numbers of the compounds correspond to the numbers of the examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
US09/462,507 1997-07-25 1998-07-18 Substituted 6-alkylphenanthridines Expired - Fee Related US6214839B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97112794 1997-07-25
EP97112794 1997-07-25
PCT/EP1998/004476 WO1999005112A1 (en) 1997-07-25 1998-07-18 Substituted 6-alkylphenanthridines

Publications (1)

Publication Number Publication Date
US6214839B1 true US6214839B1 (en) 2001-04-10

Family

ID=8227118

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/462,507 Expired - Fee Related US6214839B1 (en) 1997-07-25 1998-07-18 Substituted 6-alkylphenanthridines

Country Status (11)

Country Link
US (1) US6214839B1 (da)
EP (1) EP1000034B1 (da)
JP (1) JP2001510826A (da)
AT (1) ATE224372T1 (da)
AU (1) AU9066498A (da)
DE (1) DE69808099T2 (da)
DK (1) DK1000034T3 (da)
ES (1) ES2184318T3 (da)
PT (1) PT1000034E (da)
SI (1) SI1000034T1 (da)
WO (1) WO1999005112A1 (da)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185149A1 (en) * 2004-03-10 2007-08-09 Altana Pharma Ag Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors
US20070191413A1 (en) * 2004-03-03 2007-08-16 Atlanta Pharma Ag Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
US20080194587A1 (en) * 2005-03-02 2008-08-14 Nycomed Gmbh Novel Salts of 6-Heterocycle Substituted Hexahydrophenanthridine Derivatives
US20110076315A1 (en) * 2005-06-08 2011-03-31 C.R Bard, Inc. Grafts and Stents Having Inorganic Bio-Compatible Calcium Salt
US8003798B2 (en) 2004-03-03 2011-08-23 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US8636794B2 (en) 2005-11-09 2014-01-28 C. R. Bard, Inc. Grafts and stent grafts having a radiopaque marker
US8652284B2 (en) 2005-06-17 2014-02-18 C. R. Bard, Inc. Vascular graft with kink resistance after clamping
US9198749B2 (en) 2006-10-12 2015-12-01 C. R. Bard, Inc. Vascular grafts with multiple channels and methods for making
US9572654B2 (en) 2004-08-31 2017-02-21 C.R. Bard, Inc. Self-sealing PTFE graft with kink resistance

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320800T1 (de) 1999-08-21 2006-04-15 Altana Pharma Ag Synergistische kombination von roflumilast und salmeterol
WO2002005616A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
AU2001283935B2 (en) 2000-07-14 2006-07-13 Altana Pharma Ag Novel 6-heteroarylphenanthridines
US7329676B2 (en) 2002-08-29 2008-02-12 Nycomed Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
US7423046B2 (en) 2002-08-29 2008-09-09 Nycomed Gmbh 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1624893A2 (en) 2003-04-01 2006-02-15 Applied Research Systems ARS Holding N.V. Inhibitors of phosphodiesterases in infertility
JP4728259B2 (ja) 2004-02-18 2011-07-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 効果的なホスホジエステラーゼ（ｐｄｅ）４インヒビターとしての新規のグアニジニル置換されたヒドロキシ−６−フェニルフェナントリジン

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3243438A (en) 1962-02-23 1966-03-29 Hoffmann La Roche Octahydro phenanthridine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1199773B (de) * 1962-02-23 1965-09-02 Hoffmann La Roche Verfahren zur Herstellung von 6-Methyl-8, 9-methylendioxy-1, 2, 3, 4, 4a, 5, 6, 10b-octahydrophenanthridin und dessen Salzen
US4309545A (en) * 1980-07-28 1982-01-05 Pfizer Inc. Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3243438A (en) 1962-02-23 1966-03-29 Hoffmann La Roche Octahydro phenanthridine compounds

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883818B2 (en) 2004-03-03 2014-11-11 Takeda Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US8324391B2 (en) 2004-03-03 2012-12-04 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US9962377B2 (en) 2004-03-03 2018-05-08 Takeda Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US9387205B2 (en) 2004-03-03 2016-07-12 Takeda Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US9149479B2 (en) 2004-03-03 2015-10-06 Takeda Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US8318944B2 (en) 2004-03-03 2012-11-27 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US8003798B2 (en) 2004-03-03 2011-08-23 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US8455653B2 (en) 2004-03-03 2013-06-04 Takeda Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US20070191413A1 (en) * 2004-03-03 2007-08-16 Atlanta Pharma Ag Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
US20070185149A1 (en) * 2004-03-10 2007-08-09 Altana Pharma Ag Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors
US10582997B2 (en) 2004-08-31 2020-03-10 C. R. Bard, Inc. Self-sealing PTFE graft with kink resistance
US9572654B2 (en) 2004-08-31 2017-02-21 C.R. Bard, Inc. Self-sealing PTFE graft with kink resistance
US20080194587A1 (en) * 2005-03-02 2008-08-14 Nycomed Gmbh Novel Salts of 6-Heterocycle Substituted Hexahydrophenanthridine Derivatives
US20100190818A1 (en) * 2005-03-02 2010-07-29 Nycomed Gmbh Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
US8754218B2 (en) 2005-03-02 2014-06-17 Takeda Gmbh Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
US8354535B2 (en) 2005-03-02 2013-01-15 Nycomed Gmbh Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
US8829189B2 (en) 2005-03-02 2014-09-09 Takeda Gmbh Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
US7718668B2 (en) 2005-03-02 2010-05-18 Nycomed Gmbh Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives
US20110076315A1 (en) * 2005-06-08 2011-03-31 C.R Bard, Inc. Grafts and Stents Having Inorganic Bio-Compatible Calcium Salt
US8652284B2 (en) 2005-06-17 2014-02-18 C. R. Bard, Inc. Vascular graft with kink resistance after clamping
US9155491B2 (en) 2005-11-09 2015-10-13 C.R. Bard, Inc. Grafts and stent grafts having a radiopaque marker
US8636794B2 (en) 2005-11-09 2014-01-28 C. R. Bard, Inc. Grafts and stent grafts having a radiopaque marker
US9198749B2 (en) 2006-10-12 2015-12-01 C. R. Bard, Inc. Vascular grafts with multiple channels and methods for making

Also Published As

Publication number Publication date
AU9066498A (en) 1999-02-16
SI1000034T1 (en) 2003-04-30
WO1999005112A1 (en) 1999-02-04
DE69808099T2 (de) 2003-05-15
DK1000034T3 (da) 2003-01-27
PT1000034E (pt) 2003-02-28
EP1000034A1 (en) 2000-05-17
EP1000034B1 (en) 2002-09-18
JP2001510826A (ja) 2001-08-07
ATE224372T1 (de) 2002-10-15
ES2184318T3 (es) 2003-04-01
DE69808099D1 (de) 2002-10-24

Similar Documents

Publication Publication Date Title
US6191138B1 (en) Phenanthridines
AU756349B2 (en) Substituted 6-phenylphenanthridines
US6410551B1 (en) Tetrazole derivatives
US6127378A (en) Phenanthridines substituted in the 6 position
US6214839B1 (en) Substituted 6-alkylphenanthridines
EP1537086A2 (en) Novel phenanthridines
US6534518B1 (en) Polysubstituted 6-phenylphenanthridines with PDE-IV inhibiting activity
AU757198B2 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
US6534519B1 (en) Phenanthridine-N-oxides with PDE-IV inhibiting activity
EP1147088B1 (en) 6-arylphenanthridines with pde-iv inhibiting activity
US6538005B2 (en) Phenanthridine-N-oxides with PDE-IV inhibiting activity
US6376485B1 (en) Benzoxazoles with PDE-inhibiting activity
AU782908B2 (en) Phenanthridine-N-oxides
AU707058B2 (en) Novel phenanthridines
US6294564B1 (en) Benzimidazoles and benzoxazoles
WO2002006239A1 (en) Phenanthridine n-oxides

Legal Events

Date Code Title Description
AS Assignment

Owner name: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GUTTERER, BEATE;REEL/FRAME:010634/0756

Effective date: 19991210

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: ALTANA PHARMA AG, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH;REEL/FRAME:013128/0431

Effective date: 20020701

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130410